SINGAPORE (Reuters) – AstraZeneca said on Friday it will supply Singapore with its COVID-19 antibody cocktail, Evusheld, by the end of the year.
Evusheld can act as another layer of protection, alongside vaccines, for people who are at high risk of COVID-19 infection, according to AstraZeneca’s statement.
The company did not specify how many courses of the treatment would be supplied to the Southeast Asian city-state.
Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!
By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.
The U.S. Food and Drug Administration on Wednesday authorised the use of Evusheld to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.
(Reporting by Chen Lin in Singapore; Editing by Ed Davies)
Craig Upton supports UK businesses by increasing sales growth using various marketing solutions online. Creating strategic partnerships and keen focus to detail, Craig equips websites with the right tools to rank in organic search. Craig is also the CEO of iCONQUER, a UK based SEO Agency and has been working in the digital marketing arena for many years. A trusted SEO consultant and trainer, Craig has worked with British brands such as FT.com, djkit.com, Development Finance, Serimax and has also supported UK doctors, solicitors and property developers to gain more exposure online. Craig has gained a wealth of knowledge using Google and is committed to creating new opportunities and partnerships.
